舒利迭联合白三烯拮抗剂扎鲁司特治疗成年哮喘的临床研究

目的探讨舒利迭联合白三烯拮抗剂扎鲁司特治疗成年哮喘的临床研究。方法将我院住院治疗的128例成年哮喘患者分入对照组与观察组,两组均给予哮喘常规治疗,对照组接受舒利迭吸入治疗。给予观察组患者舒利迭联合白三烯拮抗剂扎鲁司特治疗,疗程均为12周。比较两组临床症状评分、肺功能及生活质量的差别。结果治疗后2周及4周,观察组临床症状评分显著优于对照组(P<0.05);治疗后8周及12周观察组患者FEV1改善率显著优于对照组(P<0.05);治疗后12周观察组支气管哮喘生存质量评估(AQLQ)评分显著优于对照组,差别具有统计学意义(P<0.05)。结论舒利迭联合白三烯拮抗剂扎鲁司特治疗成年哮喘,改善患者临床症状、肺功能及生活质量效果更为理想。

Clinical research on seretide and zafirlukast in the treatment of adults with asthma

Objective To explore the effect of seretide and zafirlukast in the treatment of adults with asthma. Methods 128 a- dult patients with asthma were randomly divided into two groups. All of them received the conventional treatment. The control group were treated seretide inhalation, and the experience group were given scretide and zafirlukast treatment. The total treatment course of the two groups was both 12 weeks. Clinical symptom score, pulmonary function and quality of life were compared between the two groups. Results The scores of clinical symptom in the experience group were superior to the control group 2 and 4 weeks after the treatment （ P 〈 0. 05 ）. The improvement of FEVl and AQLQ was more pronounced in the experience group than in the control group with statistical significance 12 weeks after the treatment （ P 〈 0. 05 ）. Conclusion Seretide and zafirlukast can better improve the clinical symptom scores, pulmonary function and life quality of adult patients with asthma.